The 2022 Psilocybin Depression Trial: Reading Beyond the Headline

A 2022 New England Journal of Medicine trial studied a single psilocybin session with psychological support in treatment-resistant depression. Its findings are clinical evidence to evaluate, not a stock-return forecast.

Who and what were studied

Goodwin and colleagues enrolled 233 adults with treatment-resistant depression and compared three assigned psilocybin conditions with psychological support. The primary analysis examined depression symptom scores at three weeks.

The intervention was not an unsupervised mushroom product and was not a microdosing routine. Its participants and support framework define what the result can reasonably be applied to.

What the primary comparison found

The highest studied condition produced a greater reduction in MADRS depression scores than the lowest-dose comparator at week three. The intermediate-versus-lowest comparison was not significant.

That pattern should be described precisely. It does not establish every dose as effective, a durable effect for every participant, or a general benefit for all forms of depression.

Harms and masking matter

The report included headache, nausea, dizziness, and fatigue, as well as suicidal ideation or behavior events. Safety should not be reduced to the claim that there were no risks.

A low-dose comparator may not fully maintain masking when the experience differs between conditions. Psychological support and the brief primary comparison window also need to remain visible.

What this means for coverage

This is a report on a study published in November 2022, not a newly announced regulatory decision. A positive trial finding does not by itself answer questions about approval, commercialization, or financing.

Use company filings for financial questions and the original paper for clinical questions. They are complementary sources, not substitutes.

Sources and further reading

• Goodwin et al., NEJM (2022)
• FDA: Drug development and approval

Explore our research resources for help checking original sources.

Investment information: This article is educational, not a recommendation to buy or sell any security. Investments can lose value, including the entire amount invested. Research findings are not investment-return forecasts.

The accompanying picture is an illustrative editorial image, not a photograph of the cited study or its participants.